Posted by Tomatheus on March 12, 2013, at 19:05:06
In reply to High Dose Maoi, posted by brklyn233342 on March 12, 2013, at 17:49:18
Willyee,
There was a non-controlled study done that examined the effects of Parnate in doses ranging from 90 to 170 mg in seven patients with refractory depression. Four of the seven individuals who participated in the study experienced remission, and a fifth participant had a partial response to the high-dose Parnate. The doses prescribed to the participants are as follows:
Patient 1: 120 mg
Patient 2: 170 mg
Patient 3: 100 mg
Patient 4: 130 mg
Patient 5: 120 mg
Patient 6: 170 mg
Patient 7: 90 mgSo, of the seven patients who participated in the above-mentioned study, five were taking doses higher than 100 mg. However, two of the participants discontinued treatment, one because of post-micturational syncope, and the other because of weight gain.
Here's what the study said regarding adverse effects of high-dose Parnate:
"Physician and patient reported treatment emergent symptoms were recorded at each interview. ... Two subjects discontinued treatment because of adverse events. Subject 2 (a nonresponder) attained a daily dose of 170 mg and experienced a single dose of post-micturational syncope, while patient 1 (a responder) electively reduced her maximum daily dose of 120 mg because of a 28 pound weight gain. Overall, every patient experienced some mild side effects, while 4 experienced moderate and 2 severe side effects. None of the adverse reactions were life-threatening, and there were no "tyramine reactions" observed. The most frequent side effects were sympatholytic (e.g. lightheadedness, impotence, urinary tract symptoms), and gastrointestinal (e.g. weight gain, carbohydrate craving). Several idiosyncratic events (post-micturational syncope, joint pains, diminished taste perception) occurred at higher doses. Interestingly, with the exception of the single episode of postmicturational syncope at 170 mg, most of the autonomic events that were experienced, occurred within the low to moderate dosage range. Paraxodically, these events diminished in intensity, or completely disappeared, at higher doses. While the paucity of side effects at high tranylcypromine doses is intriguing, these data must be interpreted with caution due to several caveats: the small sample size, the a priori expectations of patients refractory to many previous medications, and the lack of a comparison treatment group."
And here's a link to the study's abstract:
http://www.ncbi.nlm.nih.gov/pubmed/2710808Tomatheus
Dx: schizoaffective disorder
Treatments: Abilify & vitamin D3
tomatheus.blogspot.com
poster:Tomatheus
thread:1040149
URL: http://www.dr-bob.org/babble/20130308/msgs/1040159.html